Sugi Predict

Sugi Predict / Compounds / SCHEMBL402743

SCHEMBL402743

SCHEMBL402743

Cc1ccc(NC(=O)Nc2cc(CN3CCC(N(C)C(=O)OC(C)C)CC3)ccc2F)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.40
▸ GALR3 O60755 1/20 0.40
▸ DRD2 P14416 2/20 0.40
▸ ADRA1A P35348 2/20 0.40
▸ CCR3 P51677 6/20 0.40
▸ ACKR3 P25106 2/20 0.39
▸ MAPK8 P45983 1/20 0.38
▸ MAPK10 P53779 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ GPR119 Q8TDV5 1/20 0.38
▸ CTNNB1 P35222 1/20 0.38
▸ TCF7L2 Q9NQB0 1/20 0.38
▸ KCNQ3 O43525 1/20 0.38
▸ KCNQ2 O43526 1/20 0.38
▸ PIK3CA P42336 1/20 0.37
▸ MTOR P42345 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL400464 0.95 CCR3 (0.39) RAB9AGALR3DRD2ADRA1ACCR3
SCHEMBL402784 0.95 CCR3 (0.39) RAB9AGALR3DRD2ADRA1ACCR3
SCHEMBL401209 0.92 RAB9A (0.44) RAB9AGALR3DRD2ADRA1ACCR3
SCHEMBL401772 0.91 MEN1 (0.40) RAB9ACCR3MAPK8MAPK10KCNH2
SCHEMBL545946 0.91 MEN1 (0.40) RAB9ACCR3MAPK8MAPK10KCNH2
SCHEMBL398774 0.91 ALDH1A1 (0.44) RAB9AGALR3DRD2ADRA1ACCR3
SCHEMBL402485 0.90 CCR3 (0.43) RAB9AGALR3DRD2ADRA1ACCR3
SCHEMBL545115 0.89 KCNH2 (0.45) RAB9AGALR3CCR3ACKR3MAPK8
SCHEMBL402744 0.88 RAB9A (0.40) RAB9AGALR3DRD2ADRA1ACCR3
SCHEMBL398569 0.87 RAB9A (0.41) RAB9AGALR3CCR3NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US claimed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US claimed
EP-2862859-A2 Compounds, compositions and methods Cytokinetics, Inc. (US) 2015-04-22 — — EP claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
US-8110595-B2 Ureas and their use in the treatment of heart failure CYTOKINETICS, INC. (US) 2012-02-07 — — US claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US claimed
US-12264133-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2025-04-01 — — US disclosed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
EP-1959960-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2008-08-27 — — EP disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
WO-2007070683-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2007-06-21 — — WO disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 RAB9A 3170/4885GALR3 4019/4885DRD2 4660/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 RAB9A 2091/4885GALR3 4620/4885DRD2 4395/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 RAB9A 2773/4885GALR3 4008/4885DRD2 4679/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RAB9A 2773/4885GALR3 4008/4885DRD2 4679/4885
US-12264133-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 RAB9A 2773/4885GALR3 4008/4885DRD2 4679/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RAB9A 2773/4885GALR3 4008/4885DRD2 4679/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 RAB9A 3170/4885GALR3 4019/4885DRD2 4660/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 RAB9A 3510/4885GALR3 1699/4885DRD2 4712/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RAB9A 2773/4885GALR3 4008/4885DRD2 4679/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 RAB9A 2773/4885GALR3 4008/4885DRD2 4679/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 RAB9A 2773/4885GALR3 4008/4885DRD2 4679/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RAB9A 2773/4885GALR3 4008/4885DRD2 4679/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 RAB9A 2773/4885GALR3 4008/4885DRD2 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.